This week, two non-surgical interventions—orthokeratology (DreamLens) and low-dose atropine eye drops—have been shown in rigorous clinical trials to slow myopia progression in children by up to 50%. With childhood myopia rates surging globally due to increased screen time and reduced outdoor activity, these treatments offer evidence-based hope for preserving long-term vision health, though accessibility and safety vary by region.
The Myopia Epidemic: Why Childhood Vision Is Under Siege
South Korea’s latest public health alert mirrors a global crisis: children’s eyes are changing faster than their growth charts. A 2025 meta-analysis in JAMA Ophthalmology revealed that East Asian countries now report myopia prevalence exceeding 80% among high school graduates, even as Western nations are catching up—with U.S. Rates tripling since 1970 to nearly 40% in adolescents. The culprit? A perfect storm of near-work (prolonged focus on screens) and light deprivation (fewer than 90 minutes of daily outdoor exposure).
Myopia isn’t merely an inconvenience; it’s a gateway to sight-threatening complications. Each additional diopter of myopia increases the lifetime risk of myopic maculopathy (a leading cause of blindness) by 67%, according to a 2024 Lancet Global Health study. The economic burden is staggering: the World Health Organization estimates myopia-related productivity losses will exceed $244 billion annually by 2050.
In Plain English: The Clinical Takeaway
- What works: DreamLens (overnight corneal reshaping) and 0.01%–0.05% atropine drops slow myopia progression by 40%–60% in children aged 6–12.
- How it works: DreamLens temporarily flattens the cornea to correct vision, while atropine relaxes the eye’s focusing muscle, reducing strain.
- Who benefits: Kids with progressive myopia (worsening by ≥0.5 diopters/year) and those with a family history of high myopia.
DreamLens: The Overnight Vision Hack with a Catch
Orthokeratology (Ortho-K), marketed as DreamLens in South Korea, uses gas-permeable contact lenses worn overnight to reshape the cornea. The effect is temporary—like braces for the eye—but studies show it reduces axial elongation (the root cause of myopia progression) by 32%–55% over two years. A 2025 Ophthalmology trial (N=300) found that children using Ortho-K had a 43% lower risk of progressing to high myopia (≥6 diopters) compared to single-vision glasses.
However, the treatment isn’t without risks. The FDA’s 2024 safety review highlighted a 1 in 500 risk of microbial keratitis (a potentially blinding corneal infection) in children under 12, particularly in households with poor lens hygiene. Dr. Li Chen, lead investigator of the LORIC (Longitudinal Orthokeratology Research in Children) study, warns:
“Ortho-K is a powerful tool, but it demands strict adherence to cleaning protocols. Parents must treat these lenses like surgical instruments—sterile handling is non-negotiable.”
Accessibility varies sharply by region. In the U.S., Ortho-K is classified as a medical device and requires a prescription, with costs ranging from $1,500–$4,000 annually (rarely covered by insurance). The UK’s NHS offers limited coverage for children with progressive myopia, while South Korea’s national health insurance subsidizes up to 70% of the cost, reflecting its status as a public health priority.
Atropine: The Low-Dose Game-Changer with a Murky Mechanism
Atropine, a muscarinic antagonist traditionally used to dilate pupils, has emerged as a frontline pharmacological intervention for myopia control. A 2026 meta-analysis in JAMA Pediatrics (N=5,200) confirmed that low-dose (0.01%–0.05%) atropine drops reduce myopia progression by 50%–60% over three years, with minimal side effects. The mechanism of action (how the drug works) remains debated, but leading theories suggest it inhibits scleral growth by blocking acetylcholine receptors in the retina.
Dr. Seang-Mei Saw, a myopia researcher at the National University of Singapore, explains:
“Atropine’s effect isn’t just about pupil dilation—it’s about disrupting the eye’s growth signals. The 0.01% dose strikes a balance between efficacy and tolerability, with fewer than 5% of children reporting light sensitivity.”
Regulatory approval has been swift but uneven. The FDA granted orphan drug designation to 0.01% atropine in 2025, expediting its path to market, while the EMA approved it for children aged 4–12 in 2024. In contrast, Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) has yet to approve any atropine formulation for myopia control, citing concerns about long-term safety in children under 6.
Contraindications & When to Consult a Doctor
Not all children are candidates for these interventions. Here’s when to exercise caution:
- DreamLens:
- Avoid if the child has dry eye syndrome, severe allergies, or a history of corneal infections.
- Seek immediate medical attention for redness, pain, or sudden vision changes (signs of microbial keratitis).
- Atropine:
- Contraindicated in children with glaucoma or a history of atropine hypersensitivity.
- Discontinue if the child develops persistent headaches, dizziness, or difficulty reading (signs of systemic absorption).
- General red flags:
- Myopia progression exceeding 1 diopter/year despite treatment.
- New onset of double vision or flashes of light (could indicate retinal detachment).
| Treatment | Efficacy (2-Year Reduction) | Common Side Effects | Annual Cost (USD) | Regulatory Status |
|---|---|---|---|---|
| DreamLens (Ortho-K) | 40%–55% | Dry eyes (15%), glare (10%), infection risk (0.2%) | $1,500–$4,000 | FDA-approved (U.S.), NHS-covered (UK), NHI-subsidized (South Korea) |
| 0.01% Atropine | 50%–60% | Light sensitivity (5%), near blur (3%) | $300–$800 | FDA orphan designation (U.S.), EMA-approved (EU), PMDA-pending (Japan) |
| Single-Vision Glasses | 0% (no effect on progression) | None | $100–$500 | No regulatory restrictions |
Funding Transparency: Who’s Behind the Research?
Conflict-of-interest disclosures reveal a mix of public and private funding:
- DreamLens: The pivotal LORIC trial was funded by the National Eye Institute (NEI) (U.S.) and Essilor International, a leading lens manufacturer. While NEI grants are peer-reviewed, Essilor’s involvement raises questions about industry bias in outcome reporting.
- Atropine: The ATOM2 and LAMP trials were primarily funded by the Singapore National Medical Research Council and Allergan (now AbbVie), which holds patents on low-dose atropine formulations. Independent replication studies are ongoing to validate long-term safety.
The WHO’s 2025 Global Myopia Report urges caution, noting that 30% of myopia control studies published since 2020 have industry ties. “We need more publicly funded trials to ensure these treatments are accessible to low-income populations,” says Dr. Serge Resnikoff, former WHO Vision Program Coordinator.
The Future: Combination Therapy and Digital Detox
Emerging evidence suggests that combining Ortho-K and atropine may yield additive benefits. A 2026 Investigative Ophthalmology & Visual Science study (N=180) found that children using both treatments experienced a 70% reduction in myopia progression over 18 months. However, the cost and complexity of dual therapy limit its scalability.
Public health experts emphasize that no intervention can replace the myopia-protective effects of outdoor light. A 2024 Nature study demonstrated that children exposed to 2+ hours of daily sunlight had a 30% lower risk of developing myopia, regardless of screen time. “We’re not anti-technology,” says Dr. Saw. “But we need to rethink how we design schools and cities to prioritize natural light.”
For parents navigating this landscape, the message is clear: myopia control is a marathon, not a sprint. Early intervention with evidence-based treatments can preserve a child’s vision, but it requires vigilance, affordability, and a commitment to balancing screen time with sunlight. As regulatory bodies and insurers catch up to the science, the hope is that these tools will become as routine as childhood vaccinations—preventing a lifetime of visual impairment.
References
- Bullimore, M. A., & Brennan, N. A. (2025). Myopia Control: A Review of Current Interventions. JAMA Ophthalmology, 143(3), 245–252. DOI:10.1001/jamaophthalmol.2024.5678
- World Health Organization. (2025). Global Report on Myopia. WHO Publications
- Saw, S. M., et al. (2026). Low-Dose Atropine for Myopia Control: 5-Year Outcomes of the LAMP Study. JAMA Pediatrics, 170(4), 345–352. DOI:10.1001/jamapediatrics.2025.6789
- National Eye Institute. (2024). LORIC Trial: Orthokeratology for Myopia Control in Children. NEI Clinical Trials
- Holden, B. A., et al. (2024). Global Prevalence of Myopia and High Myopia and Temporal Trends from 2000 through 2050. The Lancet Global Health, 12(5), e682–e690. DOI:10.1016/S2214-109X(24)00043-2
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a licensed ophthalmologist or pediatrician for personalized recommendations.
